Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain
- PMID: 721318
- DOI: 10.1002/ijc.2910220513
Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain
Abstract
An H-2 heterozygous sarcoma, MDAY, originally induced with methylcholanthrene in an (A X DBA/2)F1 ((H-2a X H-2d) hybrid host was selected for growth in the H-2d homoxygous parental DBA/2 strain by serial intraperitoneal transplantation of ascites tumor cells. An apparent variant, designated MDAY-D2, was obtained which showed the expected loss of the private and public H-2Kk haplotype antigens normally associated with the A strain parent and the original MDAY tumor. Comparison of the original and variant lines revealed a wide variety of a cell surface antigen and receptor differences. Both tumors were found to be highly anaplastic and histologically unclasssifiable. Examination of the two tumor lines growing in vivo revealed a remarkable difference in their metastatic growth potential. The original MDAY line showed little propensity to spread to any organ site, with the occasional exception of liver, after subcutaneous inoculation of (A X DBA/2)F1 mice. In striking contrast, there was a rapid and massive spread of MDAY-D2 to liver, spleen, lungs and kidneys within 12-16 days: liver and spleen could be totally replaced by tumor within 2-3 weeks. These characteristics were observed in both (A X DBA/2)F1 and DBA/2 mice. The tendency to metastasize, as well as loss of the H-2Kk haplotype, appeared stable and irreversible. Although the precise origin of MDAY-D2 is not clear, its metastasizing properties are unique, making it a useful and desirable model to study the biology of metastasis.
Similar articles
-
Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor.Mol Cell Biol. 1983 Apr;3(4):523-38. doi: 10.1128/mcb.3.4.523-538.1983. Mol Cell Biol. 1983. PMID: 6687920 Free PMC article.
-
Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor.J Natl Cancer Inst. 1980 May;64(5):1221-30. J Natl Cancer Inst. 1980. PMID: 6929020
-
Immune-mediated arrest and reversal of established visceral metastases in athymic mice.Cancer Res. 1979 Oct;39(10):4034-41. Cancer Res. 1979. PMID: 476640
-
Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.Cancer Metastasis Rev. 1982;1(2):99-140. doi: 10.1007/BF00048223. Cancer Metastasis Rev. 1982. PMID: 6764377 Review.
-
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells.Cancer Metastasis Rev. 1984;3(1):5-24. doi: 10.1007/BF00047690. Cancer Metastasis Rev. 1984. PMID: 6370419 Review.
Cited by
-
Sensitivity to thermochemotherapy of AKR lymphoma and B16 melanoma variants of malignancy.Clin Exp Metastasis. 1990 Jan-Feb;8(1):33-46. doi: 10.1007/BF00155591. Clin Exp Metastasis. 1990. PMID: 2293912
-
Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor.Mol Cell Biol. 1983 Apr;3(4):523-38. doi: 10.1128/mcb.3.4.523-538.1983. Mol Cell Biol. 1983. PMID: 6687920 Free PMC article.
-
Experimental systems for analysis of the malignant phenotype.Cancer Metastasis Rev. 1982;1(2):141-99. doi: 10.1007/BF00048224. Cancer Metastasis Rev. 1982. PMID: 6764376 Review.
-
Development of lymphosarcoma lines with high metastatic ability to lymph nodes and visceral organs in BALB/c mice.Clin Exp Metastasis. 1988 Mar-Apr;6(2):141-52. doi: 10.1007/BF01784845. Clin Exp Metastasis. 1988. PMID: 2449989
-
Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.Clin Exp Metastasis. 1987 Apr-Jun;5(2):147-56. doi: 10.1007/BF00058060. Clin Exp Metastasis. 1987. PMID: 3594972
MeSH terms
Substances
LinkOut - more resources
Full Text Sources